ESCAPE Bio
Julie Anne Smith is the President and Chief Executive Officer at ESCAPE Bio. Julie has over 25 years of experience in the pharmaceutical and biotechnology industries. Julie has a proven track record in developing and commercializing drugs for rare and orphan diseases.
Ms. Smith joined ESCAPE Bio in July 2017 as President and CEO. Prior to joining ESCAPE Bio, Ms. Smith served as the President and CEO of Nuredis, Inc., a privately-held biopharmaceutical company developing treatments for ocular diseases. Ms. Smith has also held senior leadership positions at Raptor Pharmaceuticals, where they served as President and CEO, and Jazz Pharmaceuticals, where they served as Vice President of Commercial.
Ms. Smith holds a Bachelor’s degree in Chemistry from the University of California, Berkeley and an MBA from Stanford University.
Julie Anne Smith received a BS in Biology from Cornell University.
Nick France - Vice President, Clinical Research, Brian Edquist - Vice President – R&D Operations, and Mari Maurer - VP, Clinical Operations report to Julie Anne Smith.
This person is not in any offices
ESCAPE Bio
ESCAPE Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. We are passionate about making a meaningful clinical impact for patients suffering from CNS diseases and believe in a genetically defined approach to achieving this goal